
Taysha Gene Therapies TSHA
$ 4.53
0.89%
Quarterly report 2025-Q3
added 11-04-2025
Taysha Gene Therapies Total Current Liabilities 2011-2026 | TSHA
Annual Total Current Liabilities Taysha Gene Therapies
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26.2 M | 36.8 M | 62.8 M | 51.7 M | 7.13 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 62.8 M | 7.13 M | 36.9 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AbCellera Biologics
ABCL
|
64.3 M | $ 3.56 | 2.01 % | $ 1.06 B | ||
|
Acorda Therapeutics
ACOR
|
228 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
1.93 M | - | 4.01 % | $ 150 M | ||
|
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | ||
|
I-Mab
IMAB
|
576 M | - | - | $ 866 M | ||
|
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | ||
|
AgeX Therapeutics
AGE
|
5.91 M | - | -10.17 % | $ 12.2 K | ||
|
Aptorum Group Limited
APM
|
4.34 M | $ 0.79 | -0.79 % | $ 4.31 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
45.3 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
5.75 M | - | 10.36 % | $ 9.8 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | ||
|
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | ||
|
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | ||
|
Arcturus Therapeutics Holdings
ARCT
|
36.4 M | $ 6.63 | -0.75 % | $ 182 M | ||
|
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - | ||
|
Akero Therapeutics
AKRO
|
39.8 M | - | - | $ 3.67 B | ||
|
Athersys
ATHX
|
29.9 M | - | 3.77 % | $ 22.4 M | ||
|
Akouos
AKUS
|
16.8 M | - | 0.23 % | $ 488 M | ||
|
Acer Therapeutics
ACER
|
19 M | - | 2.71 % | $ 14 M | ||
|
ARCA biopharma
ABIO
|
13 M | - | 1052.0 % | $ 415 M | ||
|
Allena Pharmaceuticals
ALNA
|
15.7 M | - | 3.16 % | $ 1.9 M | ||
|
AlloVir
ALVR
|
5.24 M | - | 4.14 % | $ 49.1 M | ||
|
Anika Therapeutics
ANIK
|
31.1 M | $ 14.36 | 1.13 % | $ 210 M | ||
|
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | ||
|
Aptose Biosciences
APTO
|
4.46 M | - | -45.71 % | $ 1.2 M | ||
|
AVEO Pharmaceuticals
AVEO
|
18.7 M | - | - | $ 521 M | ||
|
Atea Pharmaceuticals
AVIR
|
39.8 M | $ 6.05 | -0.82 % | $ 493 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | ||
|
Aytu BioScience
AYTU
|
63.1 M | $ 2.64 | 3.94 % | $ 16.6 M | ||
|
Avenue Therapeutics
ATXI
|
816 K | - | -52.27 % | $ 4.45 M | ||
|
BioCardia
BCDA
|
3.61 M | $ 1.27 | 0.79 % | $ 26.9 M | ||
|
Autolus Therapeutics plc
AUTL
|
60.7 M | $ 1.51 | 4.86 % | $ 385 M | ||
|
Athira Pharma
ATHA
|
13.1 M | - | - | $ 269 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
2.05 M | $ 3.58 | -0.56 % | $ 7.79 B | ||
|
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | ||
|
Actinium Pharmaceuticals
ATNM
|
8.15 M | $ 1.11 | - | $ 33.4 M |